News
4th December 2025
Merakris Therapeutics Announces Completion of Type C Meeting with FDA – Alignment on MTX-001 Biologic Drug Development Pathway
4th September 2025
Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025
19th August 2025
Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform
24th July 2025